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ABSTRACT
We previously evaluated the short-term follow-up prelim-
inary data of mesenchymal stem cells (MSCs) transplan-
tation in patients with ischemic stroke. The present study
was conducted to evaluate the long-term safety and efﬁ-
cacy of i.v. MSCs transplantation in a larger population.
To accomplish this, we performed an open-label, observer-
blinded clinical trial of 85 patients with severe middle cer-
ebral artery territory infarct. Patients were randomly allo-
cated to one of two groups, those who received i.v.
autologous ex vivo cultured MSCs (MSC group) or those
who did not (control group), and followed for up to 5
years. Mortality of any cause, long-term side effects, and
new-onset comorbidities were monitored. Of the 52
patients who were ﬁnally included in this study, 16 were
the MSC group and 36 were the control group. Four
(25%) patients in the MSC group and 21 (58.3%) in the
control group died during the follow-up period, and the
cumulative surviving portion at 260 weeks was 0.72 in the
MSC group and 0.34 in the control group (log-rank; p 5
.058). Signiﬁcant side effects were not observed following
MSC treatment. The occurrence of comorbidities including
seizures and recurrent vascular episodes did not differ
between groups. When compared with the control group,
the follow-up modiﬁed Rankin Scale (mRS) score was
decreased, whereas the number of patients with a mRS of
0–3 increased in the MSC group (p 5 .046). Clinical
improvement in the MSC group was associated with se-
rum levels of stromal cell-derived factor-1 and the degree
of involvement of the subventricular region of the lateral
ventricle. Intravenous autologous MSCs transplantation
was safe for stroke patients during long-term follow-up.
This therapy may improve recovery after stroke depend-
ing on the speciﬁc characteristics of the patients. STEM
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INTRODUCTION
Ischemic stroke is associated with high mortality and severe
morbidity, and many stroke survivors are left with permanent
neurological disability. Although rehabilitation therapy is im-
portant for maximization of functional recovery after stroke,
once neurological deﬁcits are ﬁxed there are few options for
recovery. It has been suggested that any therapy that leads to
even slight recovery might be helpful [1]. Cell therapy could
provide trophic support or cell replacement to the infarcted
area. Various cell types are candidates for cell therapy in is-
chemic stroke (from embryonic stem cells to neuronal cell
lines), and clinical trials of neuronal differentiated tumor cell
lines [2], neural progenitor cells from primordial porcine stria-
tum [3], and autologous bone marrow-derived mesenchymal
stem cells (MSCs) [4] have been conducted. The use of
MSCs is attractive in that autologous cells may allow immune
reactions to be avoided. MSCs are multipotent and can trans-
differentiate into neural cells [5, 6]. Brain samples taken from
women who received bone marrow transplants from male
donors showed nerve cells containing Y chromosomes, sug-
gesting that MSCs function in the brain [6]. Moreover, MSCs
secrete cytokines, growth and trophic factors, which activate
mechanisms that lead to improved neurological functions such
as neurogenesis, angiogenesis, and synaptogenesis [7–11].
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Preclinical studies of brain metabolic proﬁling have shown
that i.v. MSCs infusion normalized ischemia-induced changes
in free fatty acid levels [12].
Our preliminary data revealed that i.v. infusion of autolo-
gous MSCs was feasible and safe during the short-term fol-
low-up period [4]. Although functional outcomes were
improved signiﬁcantly early after MSCs treatment, the
degrees of improvement declined until 1-year after follow-up.
In addition, there has been concern regarding the use of fetal
calf serum or fetal bovine serum (FBS) in cell culture [13].
Thus, long-term follow-up is needed to evaluate functional
outcomes and possible harmful effects of xenogeneic compo-
nents. In our preliminary study, only ﬁve patients were fol-
lowed for relatively short periods. In addition, individual
patients may have different responses to the treatment. There-
fore, patient selection is an important matter for enhancing
the efﬁcacy of MSC therapy.
Thus, the present study was conducted to evaluate the
long-term safety and functional efﬁcacy of i.v. autologous ex
vivo cultured MSCs infusion in patients with acute ischemic
stroke. In addition, we evaluated factors associated with the
response to MSC therapy.
PATIENTS AND METHODS
Study Design
This was a randomized open-labeled, observer-blinded clinical
trial of patients with ischemic stroke who had severe and per-
sistent deﬁcits and received i.v. ex vivo cultured autologous
MSCs. The clinical trial protocol and consent form were
approved by the Korean Food and Drug Administration and
the Local Institutional Review Board for Human Investigation.
We obtained written informed consent from all patients and/or
their ﬁrst-degree relatives. The study protocol is shown in
Figure 1.
Patient Enrollment and Randomization
Consecutive patients were selected from July 2003 to December
2005. Patients between 30 and 75 years of age were included in
this study only when they met the following conditions: (a) they
had been observed within 7 days of the onset of symptoms; (b)
they had relevant lesions within the middle cerebral artery terri-
tory as assessed using diffusion-weighted imaging (DWI); (c)
they had severe persistent neurologic deﬁcit (modiﬁed NIH
Stroke Scale [mNIHSS] [14] 7 points) on the seventh admission
day with stable course; and [4] they had no hematologic disorders
or bone marrow suppression. Selection of candidates on the sev-
enth admission day was based on our previous data; 748 patients
with acute (<72 hours after onset) nonlacunar infarction within
the middle cerebral artery territory were followed-up for 6
months [15]. This was because a marked improvement or worsen-
ing was frequently seen within 7 days of admission (20%), and
mNIHSS scores of at least six on day 7 after admission accu-
rately forecasted a high probability of poor long-term outcome
after middle cerebral infarctions.
We excluded patients who met any of the following condi-
tions: (a) lacunar infarction; (b) premorbid dependence; (c) hema-
tologic cause of stroke; (d) presence of severe medical illness; (e)
presence of severe febrile illness; (f) hepatic or renal dysfunction;
(g) positive response of penicillin skin test; and (h) unwillingness
to participate. Patients were randomly allocated to one of two
groups, the MSC or control group, by use of a randomization
table. The randomized allocation to groups was performed on the
seventh day of admission by a blinded, independent coordinator.
After the initial random allocation of patients to treatment groups,
experimental procedures were not blinded. Neither bone marrow
aspiration nor sham infusion was performed in the control
patients.
Preparation and Transplantation of MSCs
The same methods were used for bone marrow aspiration, isola-
tion of MSCs, cell culture, cell preparation, and i.v. infusion [4].
Brieﬂy, 5 ml of bone marrow were aspirated on the posterior iliac
crest of patients in the MSC group. The aspiration was performed
Figure 1. Study protocol.
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within 1 week after randomization to the MSC group. Bone mar-
row mononuclear cells were separated by Ficoll density centrifu-
gation. Mononuclear cells were cultured in a 175 cm2 ﬂask
(Falcon, Franklin Lakes, NJ, http://www.bd.com) with low-glu-
cose Dulbecco’s modiﬁed Eagle’s medium (Gibco-BRL, Grand
Island, NY, http://www.invitrogen.com) containing 10% FBS
(Hyclone, Irvine, CA, http://www.hyclone.com), and 1% penicil-
lin–streptomycin (Sigma, St. Louis, MO, http://www.sigma-
aldrich.com) in a humidiﬁed incubator at 37C under 5% CO2.
Nonadherent cells were removed when the medium was exchanged
at the ﬁfth day. When the primary MSCs had expanded to 80%
conﬂuence, they were harvested and subcultured. Thus, autologous
MSCs were culture-expanded to reach 1  108 cells per patient,
the human dose equivalent to the dose that was effective in a rat
model of stroke (1  105 to 3  106 cells per rat) based on mean
body weight [4]. Approximately 4 weeks after bone marrow aspira-
tion (median, 32.5 days; range, 18.8–37.0), 5  107 autologous
MSCs were transplanted into patients through i.v. infusion with
100 ml of saline and the same amount of cells were again trans-
planted approximately 2 weeks after initial boosting. We used
GMP (Good Manufacturing Practice) conditions (FCB-Pharmicell
Corporation, Seongnam, South Korea, http://www.fcbpharmicell.
com) and clinical grade reagents for preparation of the cells.
Cell viability was determined by trypan blue staining at the
end of the harvest and before infusion, and the viability was greater
than 95% for every infusate at both time points. Cell culture was
tested weekly for sterility and there was no evidence of bacterial,
fungal, viral, or mycoplasmal contamination in any of the ﬂask
tests. Because stem cells are highly likely to be differentiated, the
surface expression of SH-2 (Src homology, CD105) and SH-4 on
culture-expanded MSCs were measured in each patient before i.v.
transplantation using ﬂow cytometry (FACScan; Becton-Dickinson,
Rutherford, NJ, http://www.bd.com), as previously described [4].
Each harvest of MSCs revealed a homogenous population of cells
with high side and forward scatter and high-expression levels of
SH-2 antigens (>90% of cells) in all patients.
Measurement of Safety and Efﬁcacy
All patients were evaluated according to a protocol that included
demographic data, medical history, vascular risk factors, labora-
tory tests, and stroke scales as in our previous study [4]. The
patients were followed serially for safety and efﬁcacy at 1 (ran-
domization), 4–5 (ﬁrst boosting), 7–9 (second boosting), and
14 weeks after admission, and every 3 months thereafter. Study
evaluations consisted of thorough physical and neurological
examinations and evaluations of adverse effects.
The primary outcome measure was the long-term safety pro-
ﬁle. Mortality of any cause and serious adverse effects were the
primary adverse events monitored. In addition, we monitored
long-term adverse effects that were possibly related to MSC treat-
ment and any immediate reactions after MSC treatment. Long-
term adverse effects possibly related to MSC treatment included
tumor formation (physical examination, plain x-ray, and follow-
up magnetic resonance imaging [MRI] at 1-year after treatment),
aberrant connections (newly diagnosed seizure or arrhythmia),
and zoonoses from the use of FBS (myoclonus, rapidly progress-
ing dementia, or ataxia). The immediate reaction included allergic
reactions (tachycardia, fever, skin eruption, leukocytosis), local
complications (hematoma or local infection at the site of bone
marrow aspiration), vascular obstruction (tachypnea, oliguria, or
peripheral vascular insufﬁciency), and systemic complications
(systemic infections, increased aspartate aminotransferase and ala-
nine aminotransferase, or blood nitrogen/creatinine levels).
The secondary outcome measures were the difference in func-
tional outcomes measured by the modiﬁed Rankin Scale (mRS)
at the last visit. To accomplish this, during the period of July
2008 to October 2008, the outcome was evaluated separately by
one of the authors who were blinded to clinical information. This
measurement was performed in all patients through ofﬁce inter-
view or careful telephone interview in patients who could not
visit the outpatient clinic.
Measurement of Stromal Cells Derived
Factor-1a Level in Plasma
Preclinical studies suggested that stromal cells derived factor-1a
(SDF-1a, CXCL 12) protein expression was associated with MSC
homing and that it was upregulated in the infarcted hemisphere
within 24 hours and maintained for at least 1 month after stroke
[16, 17]. The serum levels of expression of this protein were
evaluated to determine if they were associated with the patient’s
response to MSC treatment. Peripheral blood samples were drawn
from patients in the MSC group at the time of the ﬁrst infusions
of MSCs. The plasma levels of the SDF-1a were then determined
utilizing enzyme-linked immunosorbent assays (R&D Systems
Inc., Minneapolis, MN, http://www.rndsystems.com).
Measurement of Subventricular Zone Involvement
Preclinical and clinical studies have reported that hypoxic-ische-
mic insult induces activation of neurogenesis from inactive neural
progenictor cells [18–20] and that MSCs promote this process [7,
11, 21, 22]. Middle cerebral artery territory infarction often
involves the lateral border of the ipsilateral lateral ventricle (the
subventricular zone [SVZ]), where endogenous neural progenitor/
stem cells are located. Thus, we investigated the relationship
between the degree of damage of SVZ and the degree of
improvement in both the control and MSC groups during the fol-
low-up period. To accomplish this, we measured the degree of
involvement of the ipsilateral SVZ on the initial DWI at two
axial levels: (a) the upper thalamus and head of caudate nucleus
and (b) the corona radiate (7-mm-upper level). Based on the
median value of the SVZ involvement, we divided patients into a
‘‘less SVZ involvement’’ and ‘‘more SVZ involvement’’ group
(Fig. 5). The hippocampus, another brain region in which endoge-
nous neural progenitor/stem cells are located, was not considered
in the analysis as this structure is usually not involved in patients
with middle cerebral artery territory infarction.
Statistics
Mean differences between groups were compared by a t test. Addi-
tionally, a Chi-square and Mann–Whitney U test were used to
compare nonparametric values. Mortality was analyzed by a
Kaplan-Meier survival curve for each group and compared by the
log-rank test. Survival time was deﬁned as the time from admission
to death or the end of the study. Cox’s proportional hazard models
were used to investigate independent associations between mortal-
ity and the groups. Confounders included age, sex, mNIHSS score
on the seventh day of admission, and initial infarct volume on
DWI. Individual changes in the mRS between the seventh day of
admission and the day of last evaluation were analyzed by Wil-
coxon signed rank test for ordinal data and McNemar’s test for bi-
nary data (good [mRS 0–3] vs. poor [mRS 4–6] functional status).
The correlation between SDF-1a and clinical outcomes, such as
mRS and the Barthel index (BI), was analyzed by Spearman’s cor-
relation analysis. The correlation between the degree of SVZ
involvement and the degree of improvement (the reduction in the
mRS between the seventh day admission and last evaluation) was
analyzed by the Wilcoxon signed rank test. A p < .05 was taken
to indicate statistical signiﬁcance. All statistical analyses were con-
ducted using SPSS 15.0 (Chicago, IL).
RESULTS
Baseline Characteristics of Patients
Of 85 patients with acute ischemic stroke initially random-
ized, 52 were ﬁnally included in the study; 11 patients died
early or underwent hopeless discharge within 4 weeks after
randomization (before the ﬁrst boosting of MSCs); and 22
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were unwilling to participate. Sixteen patients received i.v.
autologous MSC transplantation (MSC group) and 36 did not
(control group).
The baseline characteristics are summarized in Table 1.
The age at onset, gender, vascular risk factors, etiology, and
initial clinical indices did not differ signiﬁcantly among
groups. The mean mNIHSS score and distribution of mRS on
the seventh day of admission did not differ among groups.
Mortality of Any Causes and Serious
Adverse Effects
After patient follow-up for an average of 117.8 weeks (control
group: 110.3 6 87.4 weeks and MSC group: 129.6 6 91.8
weeks), 21 patients in the control group and four patients of
the MSC group were dead, and the cumulative surviving pro-
portion at 260 weeks after randomization was 0.34 and 0.72
in the control group and the MSC group, respectively (log-
rank test: p ¼ .058; Fig. 2). Hazard ratios were calculated
with the Cox hazard proportional model, which was adjusted
for baseline age, sex, mNIHSS score on the seventh admis-
sion day, and initial stroke volume on DWI. The hazard ratio
in the MSC group was 0.344 when compared with the control
group (95% CI, 0.115–1.031; p ¼ .057).
None of the patients in the MSC group had malignant
tumor. In one patient in the MSC group, a small mass was
observed on the lateral malleolus of the left ankle 18 months
after MSC transplantation. This mass was removed by exci-
sion and shown to be eccrine poroma, which is a benign
tumor. Follow-up brain MRI including gadolinium-enhance-
ment was performed in all patients after 12 months of MSC
treatment, and the results revealed no structural changes
(including tumor formation) relative to baseline. Five patients
developed seizure after stroke in the control group, whereas
this was observed in three patients in the MSC group. Newly
diagnosed arrhythmia during the follow-up period was not
observed in any patients.
Recurrent vascular episode was observed in three patients
in the control group (one with ischemic stroke and two with
coronary heart disease), and in four patients in the MSC group
(two with ischemic stroke, one with coronary heart disease, and
one with peripheral artery occlusive disease). Among patients
in the MSC group, one had recurrent ischemic stroke 7 months
after the index stroke. This patient could not take anticoagulants
even though she had atrial ﬁbrillation because her stroke was
accompanied by hemorrhage after use of tissue plasminogen
activator. Another patient who had right cerebral infarct and
was subsequently able to walk independently with a cane com-
plained of right leg weakness at approximately 4 years after
MSC treatment. These new symptoms lasted for 10 days and
improved after hydration during hospitalization. However, no
new lesion was observed upon brain MRI.
Table 1. Baseline characteristics of patients
Control group (n ¼ 36) MSC group (n ¼ 16) p
Age 64.9 6 14.5 64.0 6 11.6 .819
Male gender 26 (72.2) 8 (50.0) .120
Hypertension 21 (58.3) 11 (68.8) .476
Diabetes 11 (30.6) 4 (25.0) .683
Cardiac problems 14 (38.9) 8 (50.0) .454
Smoking 18 (50.0) 6 (37.5) .404
Dyslipidemia 8 (22.2) 1 (6.3) .160
Prior cerebrovascular events 4 (11.1) 2 (12.5) .885
Stroke subtype .906
Atherosclerosis 17 (47.2) 7 (43.8)
Cardioembolic origin 12 (33.3) 6 (37.5)
Others 1 (2.8) 0 (0)
Unknown 6 (16.7) 3 (18.8)
mNIHSS on 7th admission day 10.17 6 3.67 10.63 6 3.03 .669
mRS on 7th admission day 4.4 6 0.9 4.8 6 0.5 .142
Left hemisphere lesion 24 (66.7) 9 (56.3) .645
Intrainfarct hemorrhage 1 (2.7) 2 (12.5) —a
Infarct volume (ml) 90.1 6 86.8 115.7 6 95.2 .358
tPA application 12 (33.3) 6 (37.5) .771
Craniectomy 1 (2.7) 2 (12.5) —a
Rehabilitationa 14 (38.9) 6 (37.5) .924
Mean follow-up period (wk) 110.3 6 87.4 129.6 6 91.8 .364
Values in parentheses represent percentage.
aConventional rehabilitation that include neurodevelopmental therapy for more than 2 weeks.
Figure 2. Kaplan-Meier survival curve showing that mortality is
lower in the MSC group than in the control group. Abbreviation:
MSC, mesenchymal stem cell.
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Zoonoses and Other Adverse Effects
Depressive mood and psychiatric features were observed in
both the control and the MSC group. However, none of the
patients in the MSC group showed myoclonus, rapidly pro-
gressing dementia, or ataxia, suggesting a prion disease.
Other possible adverse effects or comorbidities of the con-
trol and MSC group were evaluated, but no differences were
observed in the frequencies of newly onset morbidity between
groups (Table 2). No new neurological deﬁcits were immedi-
ately identiﬁed after MSC treatment. One patient had a fever
when MSCs were infused and therefore did not receive a sec-
ond booster. There was no evidence of septicemia in this
patient, but urinary tract infection was found.
Functional Outcomes
Observer-blinded evaluation of mRS was performed sepa-
rately at a median of 3.5 years after stroke in the control
group (interquartile range, 3.0–4.5 years; full range, 2.7–4.9
years) and 3.2 years after stroke in the MSC group (interquar-
tile range, 1.5–4.7 years; full range, 0.3–5.0 years; Fig. 3).
Within-group comparison was performed using the Wilcoxon
signed rank test, which took mRS at the seventh admission
day from the score at the last evaluation in each group. In the
control group, 13 of 36 patients had a negative rank, which
indicates an improved functional outcome for each patient,
whereas 21 patients had a positive rank (i.e., a worsened out-
come; z ¼ 0.412, p ¼ .681). In the MSC group, 11 of 16
patients had a negative rank, whereas only four patients had a
positive rank. There tended to be more patients with improved
outcome than with worsened outcome in the MSC group (z ¼
1.955, p ¼ .051). Additionally, the proportion of patients
with mRS 0–3 increased in the MSC group (McNemar test,
p ¼ .046), but not in the control group (p ¼ .257).
Factors Associated With the Response to MSC
Treatment: Biomarker and Neuroimaging Findings
Correlation of biomarker and functional outcomes was veri-
ﬁed by the SDF-1a level in patients within the MSC group
(n ¼ 9). Serum levels of SDF-1a at the time of MSC treat-
ment were signiﬁcantly correlated with both mRS and BI at 1
year after MSC treatment (Fig. 4). Spearman’s correlation
analysis revealed that the SDF-1a level was positively corre-
lated with BI and negatively correlated with the mRS score
(SDF-1a vs. BI, r ¼ 0.882, p ¼ .002; SDF-1a vs. mRS, r ¼
0.814, p ¼ .008).
DWI data showed that the degree of SVZ involvement
was varied among patients (median, 0.285; interquartile range,
0.098–0.485; and full range, 0–1). Functional improvement
was consistently observed in the MSC group, especially
when the SVZ was less infarcted (Wilcoxon signed rank test,
n ¼ 5, z ¼ 2.060, p ¼ .039 for MSC-less group; Fig. 5D).
However, functional improvement was not consistently
observed in other groups (Wilcoxon signed rank test, n ¼ 11,
z ¼ 0.942, p ¼ .346 for MSC-more group; n ¼ 21, z ¼
0.350, p ¼ .726 for control-less group; and n ¼ 15, z ¼
0.263, p ¼ .793 for control-more group). The infarct
volume upon initial MRI was not different among groups
(p ¼ .430).
DISCUSSION
Our preliminary short-term follow-up data revealed that i.v.
application of autologous MSCs is a feasible and safe therapy
that may improve functional recovery in stroke patients [4].
However, a long-term follow-up study is necessary for the fol-
lowing reasons. First, there have been emerging concerns
regarding the use of xenogeneic FBS during ex vivo cultivation
of MSCs [13, 23, 24]. In addition to the risk of zoonoses, Spees
et al. raised the possibility that repeated administration of
MSCs contaminated by xenogeneic proteins leads to a risk of
immunologic rejection of the injected cells and may also lead
to more serious complications such as autoimmune reactions
against one’s own stem cells [13]. Second, our preliminary
data showed that functional improvement occurred shortly after
Table 2. New onset morbidities
Disease entities
Control
group
(n ¼ 36)
MSC group
(n ¼ 16)
Early reactions
Vascular obstruction
Recurrent strokea 1 2b
Myocardial infarction or anginaa 2 1b
Peripheral artery occlusive disease 0 1b
Local complications 0 0
Systemic complications
Infection (pneumonia,
urinary tract infection)a
9 3
Acute renal failurea 1 0
Liver enzyme elevation 2 1
Allergic reactions 0 0
Long-term adverse effects
Tumor formation
Systemic cancera 1 0
Brain tumor 0 0
Mass, benign 1 1c
Aberrant connections
Seizure 5 3
Arrhythmia 0 0
Neuropyschological illnessd 7 6
aMajor causes of death.
bNo relationship between the onset of recurrent stroke and time
of administration of mesenchymal stem cells.
cEccrine poroma.
dIncluding newly developed cognitive impairments, depression,
and psychiatric features.
Figure 3. Proportion of patients in the control and MSC group
according to the mRS at day 7 of admission and last evaluation (me-
dian, 3.5 years; interquartile range, 2.9–4.6 years). Abbreviations:
mRS, modiﬁed Rankin Scale; MSC, mesenchymal stem cell.
Lee, Hong, Moon et al. 1103
www.StemCells.com
cell therapy and diminished with time [4]. Thus, it is necessary
to evaluate the long-term functional outcome to clarify the pos-
sible beneﬁcial effects of MSC transplantation.
The results of the present study showed that i.v. application
of ex vivo culture expanded MSCs is safe based on 5 years of
follow-up. The mortality rate in the MSC group was lower than
that in the control group, and there was no difference in comor-
bidities during the follow-up period. None of the patients in the
MSC group showed typical features of zoonoses. Although
additional follow-up of our patients may be needed, bovine
spongiform encephalopathy has a relatively short latent period
when compared with Creutzfeldt-Jakcob disease [25]. We have
Figure 4. Correlation between plasma SDF-1a level and clinical outcomes; (A) mRS score and (B) Barthel index. Abbreviations: mRS, modi-
ﬁed Rankin Scale; SDF-1a, stromal cells derived factor-1a.
Figure 5. Association of intactness of the SVZ with effects of MSC transplantation. (A): Examples of diffusion-weighted images of patients
with the more and less SVZ involvement. The SVZ involvement ¼ [length of infarcted SVZ (a þ b)/total length of SVZ (b þ d)]. Only the ipsi-
lateral side was considered. (B–E): The changes in the mRS scores according to the involvement of the SVZ. Improvement in functional outcome
was consistently observed only in the MSC group when the SVZ was less damaged (D). There was no signiﬁcant change of mRS in other
groups (B, C, and E). The symbol ‘‘*’’ indicates the diffusion-weighted imaging lesion volume upon admission was not different among groups.
Abbreviations: IQR, interquartile range; MSC, mesenchymal stem cell; SVZ, subventricular zone.
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also evaluated other serious adverse effects that may be associ-
ated with MSC therapy. There has been concern about arrhyth-
mia following bone marrow transplantation. Supraventricular
tachyarrhythmia was reported in patients who received hemato-
poietic stem cell transplantation [26]. Similarly, seizure may be
caused by aberrant innervation from newly formed neural cir-
cuits. In addition, vascular occlusion can be caused by MSCs at
the time of infusion via occlusion of the arteries of the brain or
other organs [27] or by restenosis [28]. In the present study, the
frequency of arrhythmia or seizure by the formation of aberrant
pathway or vascular events did not different between groups.
Our data demonstrated long-term beneﬁcial effects of MSC
therapy in terms of functional outcome and survival. Speciﬁ-
cally, functional recovery was more frequently observed in the
MSC group than in the control group. Differences in the mor-
tality rate may reﬂect these beneﬁcial effects of MSC therapy.
Besides the short-lasting effects that occurred via trophic sup-
port of MSCs, a long-lasting effect of MSCs could also be
expected [9, 10]. Enhancing neurogenesis can be a candidate
explanation of the therapeutic mechanism of MSCs. Preclinical
studies showed the importance of neurogenesis in an animal
model of stroke and transplanted MSCs might enhance this
process [7, 11, 21, 22]. Stroke-induced neurogenesis was
reported to continue for up to 1 year and to occur in aged
brains [19, 29]. This study compared the response of patients
with damaged neurogenesis systems to MSC transplantation to
that of patients with intact neurogenesis systems. To accom-
plish this, we indirectly estimated the association between
MSC transplantation and the enhancement of neurogenesis as
demonstration of neurogenesis (such as brain pathology with
bromodeoxyuridine incorporation) is not feasible in clinical tri-
als. Our neuroimaging analysis data revealed that ameliorating
changes of mRS appeared when the SVZ was less involved. In
other words, the effects of MSCs were unpredictable when the
SVZ was severely damaged. This feature was not confounded
by the infarct volume as there was no difference among groups.
Because of the experimental nature of the treatment, this study
was conducted on severely disabled patients who often had
severe damage to the periventricular areas.
In the present study, clinical improvement was correlated
with the plasma SDF-1a level at the time of MSC treatment.
Previous preclinical studies revealed that the migration of trans-
planted MSCs into the infarcted area was associated with the
SDF-1a level [16, 30, 31]. Moreover, SDF-1a/CXC chemokine
receptor-4 (CXCR4) axis mediated the migration of neural pro-
genitor cells after stroke [32]. Circulating SDF-1a may be se-
questered within the vessel wall or infarcted area in patients
with myocardial infarct or ischemic stroke [33], which may
increase the local concentration of SDF-1a. These ﬁndings sug-
gest that the SDF-1a level of early-stage stroke play an impor-
tant role in functional recovery after MSC treatment. Thus, se-
rum SDF-1a levels may be useful for screening candidate
patients who are likely to have favorable outcome after MSC
treatment. Our data raise the possible importance of selection
of good candidate patients for cell therapy. Nevertheless, our
data are not conclusive because of the small sample size, and
they do not allow elucidation of the direct cause and effect
relationships between SDF-1a levels and MSC effects. In addi-
tion, SDF-1a levels were not measured in the control group
and serial measurement was not performed in the MSC group.
LIMITATIONS AND CONCLUSIONS
Our results showed the long-term safety and possible beneﬁ-
cial effects of autologous MSCs transplantation. However,
several limitations should be mentioned. First, owing to the
experimental nature of treatment, relatively small numbers of
MSC cases were included in this study. We stopped enrolling
patients but continued follow-up due to recent concerns
regarding the risk of the use of xenogeneic serum during ex
vivo cultivation of MSCs. Second, this study was not double-
blinded; therefore, placebo effects cannot be excluded. We
could not perform bone marrow aspiration in the control
group. However, observer-blinded measurement of functional
outcome was performed, and patients were randomized so
that most baseline characteristics were similar between
groups. It has been debated whether double-blinded controlled
study is necessary for evaluation of the efﬁcacy of empirical
treatment in human trials [34, 35].
Finally, further studies are needed to enhance the beneﬁ-
cial effects of MSC transplantation. In our study, although
MSCs were administered twice with divided doses (5  107
cells) to shorten the time interval between randomization and
the ﬁrst boosting of MSCs, ex vivo cultivation took approxi-
mately 4 weeks. The time interval between the onset of stroke
and the time of cell therapy may be important in terms of the
efﬁcacy of cell therapy and thus should be shortened. Earlier
stem cell transplantation was associated with better motor
tasks in an animal study [36]. In addition, the functional
effects of MSCs including the neurogeneic potency by activat-
ing the endogeneous repair system may be decreased after ex
vivo cultivation [11].
Great potential for improving the therapeutic efﬁcacy and
safety associated with MSCs transplantation exists with fur-
ther preclinical and clinical trials. Recently, there have been
various efforts to enhance the therapeutic beneﬁcial effects of
stem cells (including blood–brain barrier manipulation, ische-
mic preconditioning, and genetically modiﬁed MSCs) [37–40]
and to reduce possible adverse effects of MSCs (use of cul-
ture media other than xenogeneic serum) [23, 41–43]. We
hope the therapeutic effects and safety of MSCs will be
improved with these efforts and suggest that the study proto-
col should be revised consequently.
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